InvestorsObserver
×
News Home

Where Will Celyad Oncology SA ADR (CYAD) Stock Go Next After It Is Higher By 1.77% in a Week?

Thursday, May 13, 2021 09:53 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Celyad Oncology SA ADR (CYAD) Stock Go Next After It Is Higher By 1.77% in a Week?

Celyad Oncology SA ADR (CYAD) stock has gained 1.77% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bearish
Celyad Oncology SA ADR has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CYAD!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CYAD Stock Today?

Celyad Oncology SA ADR (CYAD) stock is trading at $5.76 as of 9:50 AM on Thursday, May 13, a gain of $0.45, or 8.38% from the previous closing price of $5.31. The stock has traded between $5.68 and $6.00 so far today. Volume today is high. So far 190,007 shares have traded compared to average volume of 44,012 shares.

To screen for more stocks like Celyad Oncology SA ADR click here.

More About Celyad Oncology SA ADR

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Click Here to get the full Stock Score Report on Celyad Oncology SA ADR (CYAD) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App